Subscribe to Newsletter
Diagnostics Infectious disease, Omics, Microbiology and immunology

Combating Emerging Viral Threats

The Helmholtz Centre for Infection Research (HZI) is coordinating a pioneering approach to identifying and targeting the crucial virus-cell binding step in viral infections. The COMBINE project seeks to transform how scientists tackle highly pathogenic viruses, such as the Marburg virus, by focusing on their earliest interactions with host cells. 

From the moment a virus binds to and activates a host cell, the stage is set for subsequent internalization and replication. This crucial first step is, therefore, a prime target for therapeutic intervention. However, the process remains understudied due to its complexity and the technical challenges associated with high-containment pathogens.

COMBINE, led by Christian Sieben, head of HZI’s "Nano Infection Biology" group, aims to address this knowledge gap. Using the Marburg virus (MARV) as a model, the project will investigate the mechanisms of virus-cell binding and entry, identifying key molecular players and developing inhibitors that block this process.

Recurrent outbreaks of Marburg infection in previously unaffected regions, and the absence of licensed vaccines or specific antiviral treatments, underscore the urgency of developing robust countermeasures. With a mortality rate often exceeding 50 percent, the Marburg virus remains a significant global health threat.

The COMBINE project employs multidisciplinary methodology, combining advanced molecular biology, proteomics, and drug discovery techniques to analyze and disrupt the virus-cell binding step.

Key objectives of the project include:

  • Identifying Molecular Signatures: Using cutting-edge tools to map the proteins and cellular mechanisms involved in viral binding and activation.
  • Characterizing Virus-Cell Interactions: Distinguishing between the initial attachment of MARV to host cells and subsequent processes like activation and internalization.
  • Developing Novel Therapeutics: Designing inhibitors and vaccine candidates to block MARV entry and prevent infection.

“Our work will not only strengthen the global virology community with new tools and knowledge, but also increase pandemic preparedness by addressing the health threats posed by the Marburg virus and other emerging viral diseases,” said Sieben.

COMBINE represents a shift toward more targeted and mechanistic approaches to antiviral research. By focusing on virus-cell binding, the project opens new avenues for diagnostics, drug discovery, and vaccine development.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register